http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
다직종 암환자 교육·상담에 대한 설문 개발과 환자 만족도 조사
이민정,금민정,김재송,김수현,손은선,이상글,송수경,최혜진,Lee, Min Jeong,Geum, Min Jung,Kim, Jae Song,Kim, Soo Hyun,Son, Eun Sun,Lee, Sang Geul,Song, Su Kyung,Choi, Hye Jin 한국임상약학회 2018 한국임상약학회지 Vol.28 No.2
Background: Presently, a multidisciplinary team of doctors, pharmacists, nurses, and dietitians provides patient education to impart information on chemotherapy. However, studies on multidisciplinary education satisfaction are inadequate. In this study, we aimed to contribute to the improvement of quality of multidisciplinary education counseling for patients with cancer by developing a satisfaction questionnaire and analyzing the satisfaction survey. Methods: A questionnaire was developed by an expert group, and the responses were recorded using the 5-point Likert scale. After conducting a pre-test, factor analysis was performed to evaluate validity. The reliability of the questionnaire was measured by Cronbach's alpha coefficient. A satisfaction survey was conducted by self-administration method. Results: Based on the results of factor analysis, factors can be divided into two parts: "overall education" and "each team member's education" (total 14 questions). The construct validity and reliability of the questionnaire are sufficiently high. Fifty-one patients took the survey between January 2, 2018 and January 20, 2018. Twenty-six (51%) patients responded that they were "very satisfied" and 22 (43.1%) patients responded that they were "satisfied". Conclusion: By developing a questionnaire on multidisciplinary education counseling for patients with cancer, it is possible to perform evaluation and research of cancer patient education. This study will contribute to the management and improvement of quality of multidisciplinary education.
Pembrolizumab 투여로 Pseudoprogression 이후 완전 관해에 도달한 호지킨 림프종 1예
홍주현 ( Joohyun Hong ),배주환 ( Joohwan Bae ),이상글 ( Sang Geul Lee ),임민기 ( Mingi Lim ),고영혜 ( Young Hye Ko ),김석진 ( Seok Jin Kim ),김원석 ( Won Seog Kim ) 대한내과학회 2017 대한내과학회지 Vol.92 No.4
Classical Hodgkin lymphoma (cHL) is a highly curable disease, but the prognosis for relapsed/refractory cHL is grave. Pembrolizumab has recently shown impressive effects in patients with relapsed/refractory cHL in a phase Ib study (KEYNOTE-013). This report presents a case of a 17-year-old male with refractory cHL who received multiple chemotherapy regi-mens and radiotherapies, including brentuximab vedotin. Following both the second and fourth cycles of intravenous pem-brolizumab 100 mg (2 mg/kg), positron emission tomography/computed tomography (PET/CT) scan showed progression. However, because performance status and fever improved, treatment was continued, and complete remission was confirmed by PET/CT after eight cycles of pembrolizumab. This case suggests that clinicians need to be aware of the potential for pseudoprog-ression in patients treated with pembrolizumab. (Korean J Med 2017;92:415-418)